Susquehanna International Group’s Aldeyra Therapeutics ALDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $186K | Sell |
109,900
-158,800
| -59% | -$696K | ﹤0.01% | 11774 |
|
|
2025
Q4 | $1.39M | Buy |
268,700
+187,700
| +232% | +$964K | ﹤0.01% | 6421 |
|
|
2025
Q3 | $423K | Sell |
81,000
-100
| -0.1% | -$521 | ﹤0.01% | 9347 |
|
|
2025
Q2 | $311K | Sell |
81,100
-30,500
| -27% | -$78.9K | ﹤0.01% | 10263 |
|
|
2025
Q1 | $642K | Buy |
111,600
+57,500
| +106% | +$340K | ﹤0.01% | 8355 |
|
|
2024
Q4 | $270K | Sell |
54,100
-23,600
| -30% | -$121K | ﹤0.01% | 10061 |
|
|
2024
Q3 | $419K | Buy |
77,700
+12,600
| +19% | +$60K | ﹤0.01% | 8891 |
|
|
2024
Q2 | $215K | Buy |
65,100
+45,300
| +229% | +$177K | ﹤0.01% | 10195 |
|
|
2024
Q1 | $64.7K | Sell |
19,800
-24,100
| -55% | -$79.3K | ﹤0.01% | 11447 |
|
|
2023
Q4 | $154K | Buy |
43,900
+25,300
| +136% | +$78.1K | ﹤0.01% | 10954 |
|
|
2023
Q3 | $124K | Sell |
18,600
-2,700
| -13% | -$20K | ﹤0.01% | 10739 |
|
|
2023
Q2 | $179K | Sell |
21,300
-141,300
| -87% | -$1.39M | ﹤0.01% | 10398 |
|
|
2023
Q1 | $1.61M | Buy |
162,600
+80,800
| +99% | +$571K | ﹤0.01% | 5622 |
|
|
2022
Q4 | $569K | Buy |
81,800
+29,100
| +55% | +$166K | ﹤0.01% | 7517 |
|
|
2022
Q3 | $281K | Sell |
52,700
-22,400
| -30% | -$134K | ﹤0.01% | 9954 |
|
|
2022
Q2 | $300K | Sell |
75,100
-219,800
| -75% | -$756K | ﹤0.01% | 9561 |
|
|
2022
Q1 | $1.31M | Sell |
294,900
-60,700
| -17% | -$242K | ﹤0.01% | 6455 |
|
|
2021
Q4 | $1.42M | Buy |
355,600
+279,400
| +367% | +$2.13M | ﹤0.01% | 6335 |
|
|
2021
Q3 | $669K | Sell |
76,200
-38,100
| -33% | -$350K | ﹤0.01% | 8631 |
|
|
2021
Q2 | $1.29M | Sell |
114,300
-95,000
| -45% | -$1.14M | ﹤0.01% | 7037 |
|
|
2021
Q1 | $2.49M | Buy |
209,300
+142,700
| +214% | +$1.64M | ﹤0.01% | 5391 |
|
|
2020
Q4 | $457K | Sell |
66,600
-22,600
| -25% | -$159K | ﹤0.01% | 8487 |
|
|
2020
Q3 | $661K | Buy |
89,200
+47,900
| +116% | +$309K | ﹤0.01% | 7088 |
|
|
2020
Q2 | $172K | Buy |
41,300
+30,500
| +282% | +$111K | ﹤0.01% | 9155 |
|
|
2020
Q1 | $27K | Sell |
10,800
-24,600
| -69% | -$111K | ﹤0.01% | 9850 |
|
|
2019
Q4 | $206K | Buy |
35,400
+25,400
| +254% | +$147K | ﹤0.01% | 8710 |
|
|
2019
Q3 | $53K | Sell |
10,000
-35,400
| -78% | -$191K | ﹤0.01% | 9757 |
|
|
2019
Q2 | $272K | Sell |
45,400
-12,200
| -21% | -$91.8K | ﹤0.01% | 8511 |
|
|
2019
Q1 | $520K | Buy |
57,600
+8,600
| +18% | +$73.1K | ﹤0.01% | 6191 |
|
|
2018
Q4 | $407K | Buy |
49,000
+20,300
| +71% | +$208K | ﹤0.01% | 6408 |
|
|
2018
Q3 | $396K | Buy |
+28,700
| New | +$233K | ﹤0.01% | 6939 |
|
|
2018
Q2 | – | Sell |
-42,500
| Closed | -$319K | – | 9536 |
|
|
2018
Q1 | $319K | Buy |
+42,500
| New | +$323K | ﹤0.01% | 7524 |
|
Other funds holding ALDX
KCM
VCM
KCM
6CM
Susquehanna International Group's ALDX Position: Q1 2026 in Review
Susquehanna International Group increased its Aldeyra Therapeutics (ALDX) stake by 343% in Q1 2026, buying an estimated $944K and bringing the position to 278,442 shares worth $471K. The position accounts for ﹤0.01% of the portfolio, ranked #9835.
Susquehanna International Group first reported a position in ALDX in Q1 2018 and has held it in 32 quarters since. The position peaked at $10.9M in Q1 2023. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.
- Susquehanna International Group held 278,442 shares of Aldeyra Therapeutics worth $471K as of Q1 2026.
- Susquehanna International Group bought 215,535 Aldeyra Therapeutics shares in Q1 2026, an estimated $944K.
- Aldeyra Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #9835 holding.
- Susquehanna International Group first reported a position in Aldeyra Therapeutics in Q1 2018 and has held it in 32 quarters since.
- Susquehanna International Group's Aldeyra Therapeutics position peaked at $10.9M in Q1 2023.
- 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.